[E-Daily Reporter Park Jung-Soo ] Huino and Yuhan(000100)announced on the 10th that they have supplied their smart AI telemetry solution, “MEMO CUE,” to Gangneung Goryeo Hospital. Gangneung Koryo Hospital is a general hospital located in Gangneung City, Gangwon Special Self-Governing Province, and serves as a regional medical hub operating major departments such as the emergency room, internal medicine, general surgery, obstetrics and gynecology, and neurosurgery. Through the adoption of MEMO CUE, the hospital plans to establish a system for real-time monitoring of patients’ vital signs in the emergency room and general wards. The hospital aims to enhance patient safety management, reduce the workload on medical staff, and improve ward operational efficiency. Memo Q is a smart AI telemetry solution that monitors vital signs—such as electrocardiograms (ECGs)—of hospitalized patients in real time and detects abnormal signs early. By utilizing the hospital’s existing communication infrastructure, it can monitor up to 300 patients without time or location constraints. The core device, the wearable ECG monitor “MEMO Patch M,” has received U.S. Food and Drug Administration (FDA) 510(k) clearance and is designed with a defibrillation protection circuit to ensure continuous monitoring even during emergencies. Hueino plans to expand the supply of MEMO Q primarily to cardiology departments, while also broadening its application to various wards and regional medical centers that require real-time vital sign monitoring. Gil Young-jun, CEO of Huino, stated, “This supply to Gangneung Koryo Hospital is a significant example of MEMO Q being integrated into the patient monitoring system of a regional hub medical institution,” adding, “Based on our collaboration with Yuhan Corporation, we will expand supply to major medical institutions and establish ourselves as a smart patient monitoring solution with high utility in hospital settings.”
The way global private equity fund (PEF) managers invest in rental housing is evolving. Previously, most cases involved directly purchasing individual properties. However, transactions have recently e…
SK hynix has drawn a clear line regarding reports that it is pursuing the sale of its stake in its Chongqing, China, plant, stating, “Nothing has been finalized.” This is the company’s response to a r…
Medy-Tox Inc.(086900)Medytox continued its revenue growth in the second quarter of this year, driven by expanded overseas sales of botulinum toxin and dermal fillers, as well as the successful market …